Sun Pharma Completes its Acquisition of Checkpoint Therapeutics
by 
Sun Pharmaceutical Industries Limited had announced the successful completion of its acquisition of Checkpoint Therapeutics, Inc. an immunotherapy and targeted oncology company. As part of the acquisition, Sun Pharma acquires UNLOXCYTTM, the first and only FDAapproved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.
“This acquisition exemplifies Sun Pharma’s commitment to supporting patients and growing its innovative therapies business,” said Dilip Shanghvi, Chairman & Managing Director of Sun Pharma. “By adding UNLOXCYTTM, we will be able to leverage our leadership in the onco-derm space to help patients access an important treatment option while growing our product portfolio.”
“I am proud of the dedication and passion of our team at Checkpoint that allowed us to achieve the first and only FDA-approved anti-PD-L1 treatment for patients with advanced cSCC, and we are excited to enter this transaction with Sun Pharma as the next step to bringing UNLOXCYT to cSCC patients in need of a differentiated immunotherapy treatment option,” said James Oliviero, President and Chief Executive Officer of Checkpoint. “Sun Pharma is aligned with Checkpoint’s commitment to improving the lives of skin cancer patients, and I believe this transaction will maximize value for our stockholders and provide accelerated access to UNLOXCYT in the United States, Europe and other markets worldwide.”
Visit our upcoming pharma conferences – https://virtueinsight.com/upcoming-conferences/
